**Table, Supplemental Digital Content 3.** Significant differencesin prognostic scoresbetween the countries and the global cohort (country vs, global cohort).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Spain****n=84** | **Mexico****n=222** | **Korea****n=274** | **USA****n=291** | **Colombia****n=40** | **France****n=66** | **Brazil****n=90** | **India****n=366** | **Chile****n=28** | **UK****n=1,092** | **Canada****n=28** |
| **MELD** |  | 30.9 vs, 23.1\*  | 20.3 vs, 23.7\* | 24.7 vs, 23.4# |  |  | 26.5 vs, 23.4# | 22.6 vs, 23.6# | 21.2 vs, 23.5# |  |  |
| **MELD-Na** | 21.2 vs, 26.9\* | 32.7 vs, 26.2\* | 23.5 vs, 27.1\* | 28.4 vs, 26.5\* |  |  | 30.7 vs, 26.6# |  |  | 26.3 vs, 27.6# |  |
| **mDF** |  | 71.6 vs, 54.6\* | 38 vs, 57.5\* |  |  |  |  | 66.1 vs, 54.4\* | 40.9 vs,55.8# |  |  |
| **GAHS** | 9 vs, 9\* | 10 vs, 8\* | 8 vs, 9\* |  | 9 vs, 9# |  | 9 vs, 9# |  |  | 8 vs, 9\* |  |
| **ABIC** |  | 8.5 vs, 7.9\* | 7.5 vs, 8# |  | 8.8 vs, 7.9# |  |  | 7.5 vs, 8\* |  |  |  |

#p<0.05 \*p<0.001

MELD: model for end-stage liver disease, mDF: Maddrey’s discriminant function, GAHS: Glasgow alcoholic hepatitis score, ABIC: age, bilirubin, international normalized ratio and creatinine score